Loading clinical trials...
Loading clinical trials...
A Randomized, Multicenter Study Evaluating HBsAg Clearance in CHB Patients Achieving HBeAg Loss and HBV DNA <200copies/ml on Treatment With Nucleotide Analogues and Switched to Peginterferon Alfa-2a
Conditions
Interventions
Peginterferon alfa 2a
Locations
1
China
The 2nd affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Start Date
October 1, 2011
Primary Completion Date
June 1, 2016
Completion Date
December 1, 2016
Last Updated
November 3, 2011
NCT06671093
NCT06885710
NCT06263959
NCT06295328
NCT02883647
NCT04139850
Lead Sponsor
The Second Affiliated Hospital of Chongqing Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions